PRESS INFORMATION BUREAU पत्र सूचना कार्यालय GOVERNMENT OF INDIA भारत सरकार Hindu, Delhi Saturday 9th January 2016, Page: 16 Width: 8.19 cms, Height: 4.39 cms, a4, Ref: proin.2016-01-09.40.109

CANCER TREATMENT Glenmark starts studies on new drug

NEW DELHI: Glenmark Pharmaceuticals on Friday announced disc overy and initiation of enabling studies of an investigational new drug (IND) molecule targeted at cancer treatment. The novel clinical development candidate, GBR1342 is an antibody based on the company's proprietary BEAT platform, Glenmark Pharmaceuticals said in a regulatory fil ng. BEAT is Glenmark's technology for production of bi-specific antibodies. GBR1342 is the second clinical development candidate following GBR1302 based on the BEAT technology. It is also Glenmark's second clinical candidate targeting oncology indications, it added. — PTI

₽₽,